Amprenavir

Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

Product Specifications

CAS Number

[161814-49-9]

Product Name Alternative

VX-478

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HIV; HIV Protease; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/Amprenavir.html

Purity

99.55

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O[C@@H]1COCC1)N[C@@H](CC2=CC=CC=C2)[C@H](O)CN(S(=O)(C3=CC=C(N)C=C3)=O)CC(C)C

Molecular Formula

C25H35N3O6S

Molecular Weight

505.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Sadler BM, Stein DS. Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother. 2002 Jan;36 (1) :102-18.|[2]Esposito V, Verdina A, Manente L, Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. J Cell Physiol. 2013 Mar;228 (3) :640-5.|[3]Helsley RN, Sui Y, Ai N, Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice. Mol Pharmacol. 2013 Jun;83 (6) :1190-9.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.